Patent Law Weblog
recent posts
- Moderna Settles Patent Litigation with Arbutus et al.
- USPTO and DOJ Statement of Interest in Collision Communications: Another Thumb on the Scale in Favor of NPE Patent Plaintiffs
- Oasis Tooling, Inc. v. Siemens Industry Software Inc. (Fed. Cir. 2026)
- Why AI Will Not Take Over the World
- BioNTech Sues Moderna over mRNA Vaccine Technology
about
Category: Biotech/Pharma News
-
By Kevin E. Noonan — The hostility of The New York Times to patents in general (and gene patenting in particular) has been well documented (see "Anti-Patent (‘Sullivan?’) Malice by The New York Times" and "Science Fiction in The New York Times"). However, until now this bias has been confined to the editorial…
-
By Kevin E. Noonan — Craig Venter’s colleagues at the J. Craig Venter Institute show no signs that recent vocal criticism of their work in synthetic biology has made a dent in their determination to "create life" (see "Patenting Life (Really)"). They report in this week’s Science Express (an online journal of pre-publication…
-
By Kevin E. Noonan — Peter Duesberg is at it again. Pioneering virologist and molecular biologist, purported genius, and member of the U.S. National Academy of Science, Professor Duesberg is predominantly and (in)famously a scientific contrarian, quick, even eager to tell other scientists that they are wrong – not just wrong about a…
-
By Kevin E. Noonan — On a website that has been active only since late last year, scientist and web guru Moshe Pritsker is collecting videos demonstrating an ever-growing collection of scientific experiments as a way of providing the hardest part of making a new protocol work in practice: actually seeing it work. …
-
By Kevin E. Noonan — After a thorough review by a peer-review panel of the scientific data presented in a report published in its pages five years ago, the journal Nature announced on June 14, 2007 that, although representation of the data in one figure was flawed, the underlying conclusions were scientifically valid. …
-
By Kevin E. Noonan — Federal District Court Judge Patti Saris handed down her decision in a major class action suit against several pharmaceutical companies, and the pharmaceutical companies cannot be happy with the result. In re Pharmaceutical Industry Average Wholesale Price Litigation, MDL No. 1456, Civil Action No. 01-12257-PBS (D. Mass. 2007).…
-
By Kevin E. Noonan — The U.S. faces a potential crisis over the failure of the Food and Drug Administration (FDA) to properly oversee quality assurance for drugs produced by foreign generic drug companies. The risks of the current situation, detailed in an earlier post (see "The Effect of Foreign Generics on The…
-
By Kevin E. Noonan — In the face of increases in the numbers of medications available to treat ailments from the life-threatening to the annoying (or, in the case of Viagra®, embarrassing), the numbers of prescriptions taken per person, particularly the elderly, and the costs of these drugs, there is a concomitantly increased…
-
By Kevin E. Noonan — While Craig Venter is trying to synthesize a "minimal genetic complement" bacteria (see "Patent Life (Really)"), a consortium of 35 research groups from 80 research centers are attacking the problem from the other end of the phylogenetic tree: what is needed (minimally) to encode a human being? Known…
-
By Kevin E. Noonan — More important (and perhaps even more sought after) than the alchemist’s Philosopher’s Stone have been the efforts over the past several years to find a substitute for embryonic stem (ES) cells. In view of ethical considerations and the Bush Administration’s religion-based (and politically-motivated) restrictions on federal funding for…
Patent Docs 